Mind Medicine (MNMD) said Monday that a first patient has been dosed in its phase 3 Voyage study that is evaluating MM120 ODT for the treatment of generalized anxiety disorder.
The company said the trial is the first of two phase 3 studies evaluating the efficacy and safety of MM120 ODT versus placebo. Mind Medicine said the second study, called Panorama, will be conducted in the US and Europe and is expected to be initiated in H1 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。